Arbutus Biopharma Corp (LTS:0SGC)
$ 3.8501 -0.0293 (-0.76%) Market Cap: 747.58 Mil Enterprise Value: 607.19 Mil PE Ratio: 0 PB Ratio: 5.95 GF Score: 43/100

Q4 2020 Arbutus Biopharma Corp Earnings Call Transcript

Mar 04, 2021 / 01:45PM GMT
Release Date Price: $3.13 (-17.20%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Pam Murphy. Thank you. Please go ahead, ma'am.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Good morning, and thank you for joining the Arbutus Biopharma Fourth Quarter 2020 Conference Call and Webcast. On the call today are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Michael Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. Bill will begin with a summary of recent accomplishments and upcoming events and a review of Arbutus' 2021 corporate objective, followed by Gaston, Mike Sofia and Dave Hastings, who will provide clinical drug discovery and financial updates, respectively. Please note Gaston

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot